STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMPH
  4. [8-K] Amphastar Pharmaceuticals, Inc. Reports Material Event

Amphastar (NASDAQ: AMPH) adds $50 million to share buyback program

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Amphastar Pharmaceuticals reported that its Board of Directors authorized a $50 million increase to the company’s share buyback program, effective March 12, 2026. The program is intended primarily to offset dilution from equity compensation grants over time.

Repurchases may occur over an indefinite period through open-market purchases, private block trades, Rule 10b5-1 plans, privately negotiated deals, or other methods permitted by law. The timing and actual number of shares bought back will depend on the share price, corporate and regulatory requirements, and other conditions.

Positive

  • None.

Negative

  • None.

Insights

Amphastar adds $50M to a flexible, dilution-focused buyback.

Amphastar Pharmaceuticals has authorized a $50 million increase to its share repurchase program, with no set end date. The stated objective is to counteract dilution from equity compensation, signaling a focus on maintaining shareholder ownership levels as stock-based pay accumulates.

The program allows repurchases via open-market trades, private blocks, Rule 10b5-1 plans, and other lawful methods, giving management broad flexibility. Actual activity will depend on share price, regulatory requirements, and other corporate considerations, so the ultimate scale and pace of buybacks remain contingent on future conditions.

Because the authorization is incremental and timing-dependent, its impact on per-share metrics such as earnings per share will hinge on how much of the $50 million is eventually deployed. Subsequent disclosures in periodic reports or future current reports would clarify execution levels and any resulting reduction in shares outstanding.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Understanding 8-K Material Events →
0001297184false00012971842026-03-122026-03-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

​

​

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event Reported): March 12, 2026

​

Amphastar Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

​

​

​

​

​

Delaware

001-36509

33-0702205

(State or Other Jurisdiction of
Incorporation)

(Commission File Number)

(I.R.S. Employer Identification
Number)

​

​

​

​

11570 6th Street

​

Rancho Cucamonga, California

91730

(Address of Principal Executive Offices)

(Zip Code)

​

Registrant's telephone number, including area code: (909) 980-9484

​

​

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

T

​

​

​

​

​

​

Title of each class

​

Trading Symbol(s)

​

Name of each exchange on which registered

​

​

​

​

Common Stock, par value $0.0001 per share

​

AMPH

​

The Nasdaq Stock Market LLC

​

​

​

​

​

​

​

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

​

​

Item 8.01. Other Events

​

On March 12, 2026, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the share buyback program is to offset dilution created by the Company’s equity compensation programs.

Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company’s management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws.

The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.

​

​

​

​

​

​

​

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

​

​

​

 

AMPHASTAR PHARMACEUTICALS, INC.

Date: March 16, 2026

 

​

By:

/S/WILLIAM J. PETERS

 

 

​

William J. Peters

 

​

Chief Financial Officer, Executive Vice President and Treasurer

 

​

​

​

​

​

Source: View Original Filing on SEC EDGAR

FAQ

What did Amphastar Pharmaceuticals (AMPH) announce in this 8-K filing?

Amphastar Pharmaceuticals announced that its Board authorized a $50 million increase to the company’s share repurchase program. The expanded program is intended to run for an indefinite period and primarily aims to offset dilution from Amphastar’s equity compensation programs over time.

How large is the increase to Amphastar Pharmaceuticals’ share buyback program?

The Board approved a $50 million increase to Amphastar’s existing share buyback program. This added authorization provides more capacity for the company to repurchase its common stock, mainly to counter dilution from stock-based compensation and other equity awards to employees and executives.

What is the main goal of Amphastar (AMPH)’s expanded share repurchase program?

The primary goal of Amphastar’s enlarged buyback program is to offset dilution created by its equity compensation programs. By repurchasing shares, the company seeks to keep the impact of stock-based awards on existing shareholders’ ownership stakes more limited over time.

How and where can Amphastar Pharmaceuticals execute its share repurchases?

Amphastar may repurchase shares through open-market purchases, private block transactions, Rule 10b5-1 trading plans, privately negotiated transactions, or other legally permitted means. Management has discretion to choose methods that comply with Securities and Exchange Commission rules and applicable laws.

Is there an end date for Amphastar (AMPH)’s increased share buyback program?

The share buyback program, including the new $50 million increase, is expected to continue for an indefinite period of time. The timing and actual number of shares repurchased will depend on stock price, corporate and regulatory requirements, and other prevailing conditions.

What factors will influence how many Amphastar shares are repurchased?

The number of shares Amphastar ultimately repurchases will depend on several factors, including the market price of its common stock, corporate and regulatory requirements, and other conditions. These considerations will guide management’s decisions on when, how, and to what extent to execute buybacks.

Filing Exhibits & Attachments

3 documents

Other Documents